[Skip to Navigation]
March 1990

Rhesus Rotavirus Candidate Vaccine: Clinical Trial in Children Vaccinated Between 2 and 5 Months of Age

Author Affiliations

From the Department of Clinical Sciences, University of Tampere, Finland (Drs Vesikari, Rautanen, and Varis); World Health Organization Collaborating Centre for Research and Reference on Rotavirus, Birmingham, England (Mr Beards); and Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Md (Dr Kapikian).

Am J Dis Child. 1990;144(3):285-289. doi:10.1001/archpedi.1990.02150270035021

• Live attenuated oral rhesus Rotavirus candidate vaccine (strain MMU 18006 [lot RRV-1]) was evaluated for immunogenicity, safety, and clinical protection in a double-blind, placebo-controlled trial involving 200 infants aged 2 to 5 months when vaccinated. Vaccine-induced fourfold or greater rise of Rotavirus antibodies was seen in 62% of the infants. Febrile reactions of short duration on days 3 and/or 4 after vaccination occurred in 26% of the vaccine recipients. The clinical follow-up covered two Rotavirus seasons, in which serotypes 1 and 4 were prevalent. There were 16 cases of confirmed Rotavirus diarrhea in the placebo-treated group and 10 in the vaccine-treated group; from this a vaccine protection rate of 38% was derived. Clinical severity of Rotavirus diarrhea was assessed by a score; 13 cases in the placebo-treated group and 5 in the vaccine-treated group were regarded as severe or moderately severe, giving a vaccine protection rate of 67%. The rhesus Rotavirus vaccine induces partial protection against heterotypic Rotavirus disease, but the level of protection achieved with the present vaccine dose in this age group appears to be insufficient for a general Rotavirus vaccination.

(AJDC. 1990;144:285-289)